Below is an another analysis from StockTA.com.  ECTE’s signals have been increasing since I began watching it, which indicates that the trend the symbol is displaying is VERY BULLISH!

Overall: Very Bullish  (.53)  -  Short: Very Bullish (.66)  -   Intermediate: Very Bullish (.50)   -   Long: (.43)

Read below for more in-depth trending and indicator charting & data – FYI: This is definately worth a look!

(more…)

Here’s a link to Echo Therapeutics (OTCBB: ECTE) CEO Patrick H. Mooney, M.D’s presentation this week at the OneMed Finance Forum in San Francisco: http://www.ustream.tv/recorded/3953983

This gives a gret description of the company, its key products/technologies, and core markets in a quick and understandable preso. Judging from this update, things are certainly looking up for Echo this year. Enjoy!

All of the top-rated companies in stock market history share one common characteristic: A product or service breakthrough that improves life for a significant percentage of the world. Echo Therapeutics, Inc. (OTCBB: ECTE) is striving to become one of those companies by making life easier for the world’s 180 million Diabetics. The company plans to seek final FDA approval in 2010 for its “Symphony” device – the first needle-free product of its kind.

“Necessity is the mother of invention” – Plato

As a sharp fella by the name of Plato once said “necessity is the mother of invention”. In ECTE’s case, necessity is the need for the world’s surging Diabetic population to refrain from being pincushions. Most sufferers cite multiple daily needle sticks as the worst part of the disease. Therefore, it seems very likely that the first product capable of monitoring glycemic levels without needles would be extremely popular. While we’ve yet to develop a cure for deadly diseases like Cancer, HIV, recent advancements have helped drastically improve quality of life for those afflicted.

Innovation drove some huge PPS increases for leading medical device makers in ‘09, many of which recently gained FDA-approval for new products. A few high-growth scenarios that Echo Therapeutics could mimic if it does in fact bring 1 or 2 products to market over the next 12-18 months include:

Endologix (Nasdaq: ELGX) Recently gained FDA approval and began commercial production for its IntuiTrak® stent graft delivery system for aortic aneurysms. PPS rose from a low of $1.63 to a high of $4.83 on 12/29. Much like ECTE’s technology, ELGX’s product addresses the shortcomings of first generation devices and facilitates major improvements to patient comfort, quality of treatment, and mortality rates.

American Shared Hospital Services (AMEX: AMS) PPS jumped from $1.00 to $2.95 in 2009 as the company’s FDA-approved Gamma Knife, non-invasive radio-surgery Cancer treatment emerged as a best-in-class offering. It is important to note that AMS likely generated less than $20 million in annual sales during ‘09 with systems in place at roughly 19 medical centers in 17 U.S. states. While the company’s product is solid and future potential exciting, ECTE likely has more mass market appeal and should be able to generate substantially higher revenues once or, two, or three FDA-approved products reach market.

Candela Corp. (Nasdaq: CLZR) – Shares of the pioneer in laser-based cosmetic surgery devices surged from $.53 to $2.68 on expectations of a merger with Syneron (Nasdaq: ELOS) a leading global aesthetic device maker. The deal closed last week and the future looks bright for the new Syneron, which now boasts likely the strongest product offering and global reach in its market niche.

 Other prime examples of how transformational healthcare innovation translates into profits for investors include:

Merck & Co. (NYSE: MRK)- shares nearly doubled from the October 2006 announcement that the company received FDA approval for the first ever vaccine for human pappilomavirus (HPV) infection.

ECTE holds the  potential to begin commercial production of one, perhaps two FDA-approved products in 2010 that have an opportunity to command a substantial share of a combined >$12 billion target market. Therefore, we feel strongly that this year, Echo Therapeutics is positioned to deliver the type of returns generated by leading medical device companies including ELGX, AMS, and ELOS in 2009.

2010 is shaping up to be a landmark year for Echo Therapeutics, Inc. (OTCBB: ECTE).  The company’s “Symphony” continuous blood glucose monitoring (CBGM) device for Diabetics is expected to become commercially available this year and extensive testing has revealed that the product holds quite a few significant advantages over current market leaders. This is absolutely huge because the addressable market for this product is more than $10 billion and growing with every new case of Diabete’s (sidenote: more than 8% of Americans are now afflicted). Here’s the “quick are dirty” on the Symphony device and the key areas where it is better than multi-billion dollar competitors:

(more…)

Leading healthcare executives and institutional finance firms will embark upon San Francisco next week in search of “the next best thing” in the medical field. Luckily for them, Echo Therapeutics (OTCBB: ECTE) will be there to give it to them.

(more…)

As some readers have mentioned recently, Echo Therapeutics, Inc. (OTCBB: ECTE) is showing a great deal of promise to surpass many of its competitors over the next 12 to 24 months, both with regard to market penetration, sales, and PPS. DexCom, Inc. (NASDAQ: DXCM) is trading at nearly $8 per share despite logging only $9.8M in 2008 revenues and annual net income of ($55.2M). While the company’s “SEVEN” CGM product is FDA-approved, Echo’s “Symphony” system is stronger in many regards.

(more…)

Echo Therapeutics is a transdermal medical device and specialty pharmaceuticals company. Echo’s Symphony™ tCGM System is a non-invasive (needle-free), wireless, transdermal continuous glucose monitoring (tCGM) system focused on changing the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care markets.

Echo’s AzoneTS™ transdermal drug reformulation technology is focused on building a pipeline of safer and improved versions of widely-prescribed, FDA-approved specialty pharmaceutical products. Echo is developing most of its AzoneTS pipeline in accordance with the FDA’s Section 505(b)(2) guidelines. Durhalieve™, Echo’s lead AzoneTS drug candidate, is an advanced topical reformulation of triamcinolone acetonide for treatment of corticosteroid responsive dermatoses. Echo has submitted its Durhalieve New Drug Application (NDA) to the FDA.

Echo Therapeutics, Inc. (OTCBB: ECTE) gained 9.6% or $.12 today on nearly 98,000 shares traded after analyst firm Boenning & Scattergood issued an “outperform” rating on the company along with a 12-month price target of $3.

(more…)

Echo Therapeutics, Inc. (OTCBB:ECTE),  a medical device and specialty pharmaceutical company, is developing a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system for people with diabetes and for use in hospital critical care units, and for people with diabetes and a wide range of transdermal reformulations of specialty pharmaceutical products previously approved by the United States Food and Drug Administration. It offers Symphonytm tCGM System, a next-generation, non-invasive (needle-free), wireless tCGM system designed to provide on-demand blood glucose data. The company was founded in 1989 and is based in Franklin, Massachusetts.

For more information, visit: http://www.echotx.com/

Wondering where AMLN is heading? Check out the following Free Instant Analysis below – I found it extremely useful especially if you are an investor!

Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States. It sells BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection for the treatment of patients with Type II diabetes. The company also has research and development programs in the therapeutic areas of diabetes and obesity, including exenatide once weekly; Nasal Exenatide, a nasal spray formulation of exenatide for diabetes; Pramlintide and PYY 3-36 for the treatment of obesity; Leptin for the treatment of obesity and lipodystrophy; Pramlintide-Metreleptin combination product candidate for overweight or obese subjects; and second generation Amylinomimetic for weight loss. It sells its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payers. The company has collaboration agreements with Eli Lilly and Company, as well as with Alkermes, Inc. to develop exenatide once weekly for diabetes; a contract research arrangement with Kelaroo, Inc. for the commercialization of Kelaroo’s SeqR technology that is used for peptide hormone identification and optimization; a joint research collaboration agreement with BioSeek, Inc. for discovery and development of novel peptide therapeutics for inflammatory conditions; and a joint research collaboration agreement with Xenome, Ltd. for discovery and development of novel peptide hormones for a range of metabolic and musculoskeletal diseases. It also has collaboration with Pacira Pharmaceuticals, Inc. for the development of sustained release injectable products based on the DepoFoam technology platform. Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California.